283
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Madelung’s Disease: Analysis of Clinical Characteristics, Fatty Mass Distribution, Comorbidities and Treatment of 54 Patients in China

, , , , , , , & show all
Pages 2365-2375 | Published online: 06 Aug 2022

References

  • Brodie BC. Clinical lectures on surgery delivered at St. George’s Hospital. Philadelphia: Lea & Blanchard; 1846: 201–10.
  • Madelung OW. Ueber den Fetthals. Arch Klin Chir. 1888;37:106–130.
  • Brea-García B, Cameselle-Teijeiro J, Couto-González I, Taboada-Suárez A, González-álvarez E. Madelung’s disease: comorbidities, fatty mass distribution, and response to treatment of 22 patients. Aesthetic Plast Surg. 2013;37(2):409–416. doi:10.1007/s00266-012-9874-5
  • Pollock M, Nicholson G, Nukada H, Cameron S, Frankish P. Neuropathy in multiple symmetric lipomatosis. Madelung’s disease. Brain. 1988;111(5):1157–1171. doi:10.1093/brain/111.5.1157
  • Chen C, Fang Q, Wang X, et al. Madelung’s disease: lipectomy or liposuction? Biomed Res Int. 2018;2018:3975974. doi:10.1155/2018/3975974
  • Vassallo G, Mirijello A, Tarli C, et al. Madelung’s disease and acute alcoholic hepatitis: case report and review of literature. Eur Rev Med Pharmacol Sci. 2019;23(14):6272–6276. doi:10.26355/eurrev_201907_18448
  • Hirose A, Okada Y, Morita E, Tanaka Y. Benign symmetric lipomatosis associated with alcoholism. Intern Med. 2006;45(17):1001–1005. doi:10.2169/internalmedicine.45.1791
  • Jang JH, Lee A, Han SA, Ryu JK, Song JY. Multiple Symmetric lipomatosis (Madelung’s Disease) presenting as bilateral huge gynecomastia. J Breast Cancer. 2014;17(4):397–400. doi:10.4048/jbc.2014.17.4.397
  • Gao Y, Hu JL, Zhang XX, Zhang MS, Lu Y. Madelung’s disease: is insobriety the chief cause? Aesthetic Plast Surg. 2017;41(5):1208–1216. doi:10.1007/s00266-017-0920-1
  • Liu Q, Lyu H, Xu B, Lee J. Madelung disease epidemiology and clinical characteristics: a systemic review. Aesthetic Plast Surg. 2021;45(3):977–986. doi:10.1007/s00266-020-02083-5
  • Enzi G, Busetto L, Ceschin E, Coin A, Digito M, Pigozzo S. Multiple symmetric lipomatosis: clinical aspects and outcome in a long-term longitudinal study. Int J Obes Relat Metab Disord. 2002;26(2):253–261. doi:10.1038/sj.ijo.0801867
  • Pinto C, Carvalho P, Correia M. Madelung’s disease: revision of 59 surgical cases. Aesthetic Plast Surg. 2017;41(2):359–368. doi:10.1007/s00266-016-0759-x
  • Chinese nutrition society, dietary guidelines for Chinese residents; 2016. Available from: http://dg.cnsoc.org/article/2007b.html. Accessed June 20, 2021.
  • Wang D, Chen J, Zhou Y, et al. Association between sleep duration, sleep quality and hyperlipidemia in middle-aged and older Chinese: the Dongfeng-Tongji cohort study. Eur J Prev Cardiol. 2019;26(12):1288–1297. doi:10.1177/2047487319843068
  • Joint committee issued Chinese guideline for the management of dyslipidemia in adults. 2016年中国成人血脂异常防治指南. [2016 Chinese guideline for the management of dyslipidemia in adults]. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44(10):833–853. Chinese. doi:10.3760/cma.j.issn.0253-3758.2016.10.005
  • National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.
  • Gao M, Lv J, Yu C, et al. Metabolically healthy obesity, transition to unhealthy metabolic status, and vascular disease in Chinese adults: a cohort study. PLoS Med. 2020;17(10):e1003351. doi:10.1371/journal.pmed.1003351
  • American Diabetes Association. 2. classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S14–S31. doi:10.2337/dc20-S002.
  • Chaker L, Bianco A, Jonklaas J, Peeters R. Hypothyroidism. Lancet. 2017;390(10101):1550–1562. doi:10.1016/s0140-6736(17)30703-1
  • Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017;390(10112):2549–2558. doi:10.1016/s0140-6736(17)32478-9
  • Singal A, Bataller R, Ahn J, Kamath P, Shah V. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol. 2018;113(2):175–194. doi:10.1038/ajg.2017.469
  • Enzi G. Multiple symmetric lipomatosis: an updated clinical report. Medicine. 1984;63(1):56–64. doi:10.1097/00005792-198401000-00004
  • Donhauser G, Vieluf D, Ruzicka T, Braun-Falco O. Benigne symmetrische lipomatose launois-bensaude Typ III und Bureau-Barrière-Syndrom [Benign symmetric Launois-Bensaude type III lipomatosis and Bureau-Barrière syndrome]. Hautarzt. 1991;42(5):311–314.
  • Prantl L, Schreml J, Gehmert S, et al. Transcription profile in sporadic multiple symmetric lipomatosis reveals differential expression at the level of adipose tissue-derived stem cells. Plast Reconstr Surg. 2016;137(4):1181–1190. doi:10.1097/prs.0000000000002013
  • Musumeci O, Barca E, Lamperti C, et al. Lipomatosis incidence and characteristics in an Italian cohort of mitochondrial patients. Front Neurol. 2019;10:160. doi:10.3389/fneur.2019.00160
  • Plummer C, Spring PJ, Marotta R, et al. Multiple symmetrical lipomatosis–a mitochondrial disorder of brown fat. Mitochondrion. 2013;13(4):269–276. doi:10.1016/j.mito.2013.03.003
  • Caponnetto F, Manini I, Bulfoni M, et al. Human adipose-derived stem cells in Madelung’s disease: morphological and functional characterization. Cells. 2020;10(1):44. doi:10.3390/cells10010044
  • Vilà M, Gámez J, Solano A, et al. Uncoupling protein-1 mRNA expression in lipomas from patients bearing pathogenic mitochondrial DNA mutations. Biochem Biophys Res Commun. 2000;278(3):800–802. doi:10.1006/bbrc.2000.3828
  • Iglesias L, Pérez-Llantada E, Saro G, Pino M, Hernández J. Benign symmetric lipomatosis (Madelung’s disease). Eur J Intern Med. 2000;11(3):171–173. doi:10.1016/s0953-6205(00)00086-8
  • Wan SC, Huang MH, Perng CK, Liao WC. Madelung disease: analysis of clinicopathological experience in Taipei veterans general hospital. Ann Plast Surg. 2019;82(1S Suppl 1):S66–S71. doi:10.1097/SAP.0000000000001719
  • Enzi G, Busetto L, Sergi G, et al. Multiple symmetric lipomatosis: a rare disease and its possible links to brown adipose tissue. Nutr Metab Cardiovasc Dis. 2015;25(4):347–353. doi:10.1016/j.numecd.2015.01.010
  • Busetto L, Sträter D, Enzi G, et al. Differential clinical expression of multiple symmetric lipomatosis in men and women. Int J Obes Relat Metab Disord. 2003;27(11):1419–1422. doi:10.1038/sj.ijo.0802427
  • El Hasbani G, Assaker R, Nithisoontorn S, et al. Madelung’s disease leading to presenile dementia in a non-alcoholic patient. Med Arch. 2019;73(4):285–287. doi:10.5455/medarh.2019.73.285-287
  • Jung K, Lee S. A case report of Multiple Symmetric Lipomatosis (MSL) in an East Asian Female. BMC Women's Health. 2020;20(1):200. doi:10.1186/s12905-020-01055-w
  • González-García R, Rodríguez-Campo F, Sastre-Pérez J, Muñoz-Guerra M. Benign symmetric lipomatosis (Madelung’s disease): case reports and current management. Aesthetic Plast Surg. 2004;28(2):108–112. doi:10.1007/s00266-004-3123-5.
  • Kratz C, Lenard H, Ruzicka T, Gärtner J. Multiple symmetric lipomatosis: an unusual cause of childhood obesity and mental retardation. Eur J Paediatr Neurol. 2000;4(2):63–67. doi:10.1053/ejpn.2000.0264
  • Lemaitre M, Chevalier B, Jannin A, Bourry J, Espiard S, Vantyghem M. Multiple symmetric and multiple familial lipomatosis. Presse Med. 2021;50(3):104077. doi:10.1016/j.lpm.2021.104077
  • Ceni E, Mello T, Galli A. Pathogenesis of alcoholic liver disease: role of oxidative metabolism. World J Gastroenterol. 2014;20(47):17756–17772. doi:10.3748/wjg.v20.i47.17756
  • Louvet A, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol. 2015;12(4):231–242. doi:10.1038/nrgastro.2015.35
  • Pan C, Ju T, Lee C, et al. Alcohol use disorder tied to development of chronic kidney disease: a nationwide database analysis. PLoS One. 2018;13(9):e0203410. doi:10.1371/journal.pone.0203410
  • Joo Y, Koh H, Nam K, et al. Alcohol consumption and progression of chronic kidney disease: results from the Korean cohort study for outcome in patients with chronic kidney disease. Mayo Clin Proc. 2020;95(2):293–305. doi:10.1016/j.mayocp.2019.06.014
  • Yun H, Kim H, Park J, et al. Obesity, metabolic abnormality, and progression of CKD. Am J Kidney Dis. 2018;72(3):400–410. doi:10.1053/j.ajkd.2018.02.362
  • Nehus E. Obesity and chronic kidney disease. Curr Opin Pediatr. 2018;30(2):241–246. doi:10.1097/mop.0000000000000586
  • Mallat S, Al Kattar S, Tanios B, Jurjus A. Hyperuricemia, hypertension, and chronic kidney disease: an emerging association. Curr Hypertens Rep. 2016;18(10):74. doi:10.1007/s11906-016-0684-z
  • Snyder S, Turner G, Turner A. Obesity-related kidney disease. Prim Care. 2014;41(4):875–893. doi:10.1016/j.pop.2014.08.008
  • Pöschl G, Seitz H. Alcohol and cancer. Alcohol Alcohol. 2004;39(3):155–165. doi:10.1093/alcalc/agh057
  • Salaspuro M, Mikko S. Interactions of alcohol and tobacco in gastrointestinal cancer. J Gastroenterol Hepatol. 2012;Suppl 2:135–139. doi:10.1111/j.1440-1746.2012.07017.x
  • Islami F, Goding Sauer A, Miller K, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68(1):31–54. doi:10.3322/caac.21440
  • Whiteman D, Wilson L. The fractions of cancer attributable to modifiable factors: a global review. Cancer Epidemiol. 2016;44:203–221. doi:10.1016/j.canep.2016.06.013
  • Jaźwiec P, Pawłowska M, Czerwińska K, Poręba M, Gać P, Poręba R. Madelung’s disease as an example of a metabolic disease associated with alcohol abuse-diagnostic importance of computed tomography. Int J Environ Res Public Health. 2022;19(9):5168. doi:10.3390/ijerph19095168
  • Katou F, Shirai N, Motegi K, Satoh R, Satoh S. Symmetrical lipomatosis of the tongue presenting as macroglossia. Report of two cases. J Craniomaxillofac Surg. 1993;21(7):298–301. doi:10.1016/s1010-5182(05)80351-8
  • Heike Z, Gudrun U, Frank R, Vetter H, Walger P. Multiple benign symmetric lipomatosis–a differential diagnosis of obesity: is there a rationale for fibrate treatment? Obes Surg. 2008;18(2):240–242. doi:10.1007/s11695-007-9247-3
  • Tremp M, Wettstein R, Tchang L, Schaefer D, Rieger U, Kalbermatten D. Power-assisted liposuction (PAL) of multiple symmetric lipomatosis (MSL)–a longitudinal study. Surg Obes Relat Dis. 2015;11(1):155–160. doi:10.1016/j.soard.2014.05.004
  • Faga A, Valdatta L, Thione A, Buoro M. Ultrasound assisted liposuction for the palliative treatment of Madelung’s disease: a case report. Aesthetic Plast Surg. 2001;25(3):181–183. doi:10.1007/s002660010118
  • DiBernardo B. Randomized, blinded split abdomen study evaluating skin shrinkage and skin tightening in laser-assisted liposuction versus liposuction control. Aesthet Surg J. 2010;30(4):593–602. doi:10.1177/1090820x10380707